Avert and Pet Nutrition Strengthen Biolab & Co.’s Veterinary Division with Supplements, Natural Treats, and a New Factory
With new additions to its portfolio for dogs and cats, the animal health division is showcasing new medications and industrial expansion at Pet South America 2026
Biolab & Co.’s animal health division will be at Pet South America 2026 with a 217 m² booth, highlighting the strength of its leading brands in the sector. Avert Biolab Animal Health reinforces its leadership in omega-3 with the international Friend of the Sea certification, which attests to the sustainability of the raw material, and is also launching Vonau Vet in tablet form, expanding its gastrointestinal health portfolio. Alongside it, Pet Nutrition, a pioneer in natural pet treats, announces its new 30,000-square-meter manufacturing plant in Pirassununga (SP) and the strengthening of its B2B operations in private-label brands.
Driven by high demand for premium products, Avert and Pet Nutrition combine pharmaceutical precision with industrial scale to serve everyone from pet owners to large companies in the sector. This synergy resulted in the brands’ first joint launch: the Doctor Paws line, featuring dietary supplements in chewable tablets for dogs.
Pet Nutrition: a strong presence in the B2B market, private-label brands, and a new factory.
As the leader in functional snacks in Brazil, Pet Nutrition excels in the B2B model and in private-label outsourcing for the Brazilian retail sector, maintaining long-standing partnerships with major chains in the industry. The company offers comprehensive end-to-end solutions, ranging from client briefings, market intelligence, and R&D to regulatory compliance and final manufacturing.
Pet Nutrition’s performance reflects the strong growth in the pet and animal feed markets. According to data from Claight Expert Market Research, the pet food sector in Latin America is projected to reach US$$ 18.47 billion (approximately R$$ 94.78 billion) by 2035, with Brazil accounting for nearly 60% of sales.
To keep pace with the fast-moving private-label market —a segment that generated R$ 6.3 billion in 2025 and is growing at an average rate of 9.2% per year (NielsenIQ), driven by 58% of consumers who plan to increase their purchases of these products in 2026— the company is accelerating construction of its new manufacturing plant in Pirassununga (SP).
The 30,000 m² facility will significantly expand the brand’s current capacity of 300 metric tons and is already certified under the IFS (International Featured Standards) international certification, ensuring strict global food safety standards.
“The private-label market in Brazil is at its most mature stage, and retailers need industrial partners who can keep pace with this growth while maintaining flexibility and international standards. Combining our R&D expertise with the expansion of our production capacity positions us as a strategic ally for companies seeking to maximize the profitability of their operations with functional products that offer high value-added,” says Gustavo Del Claro, Director of Pet Nutrition.
A pioneer in high-quality natural snacks designed to engage and delight dogs, the brand is expanding its portfolio with the Pet Nutrition Vie line: snacks shaped like mini steaks, made with natural ingredients and antioxidants (no artificial colors), offering specific benefits for breakfast, lunch, and dinner.
Avert Biolab Animal Health: National Leadership and International Expansion
The company is a leader in the omega-3 segment in Brazil with its Ograx line, and backed by the international Friend of the Sea certification, Avert is the first veterinary company in the world to earn the sustainable fishing seal. The scope of its operations extends beyond national borders: the brand exports its products to the Canadian market through Exzell Pharma, the group’s international division.
In Brazil, the company is the first to launch a veterinary gabapentin registered by MAPA, which is entering the market under the brand name Decrise. Developed specifically for the behavioral management of cats, the medication addresses a recurring need among veterinary professionals. Another major launch is Vonau Vet tablets, an oral version of its well-known antiemetic, developed to offer greater convenience, precision in dosing, and ease in the routine prevention and treatment of nausea and vomiting in pets—adding to a comprehensive portfolio with more than 10 SKUs dedicated to animals’ gastrointestinal health.
“With our international presence and leadership in omega-3 in Brazil, we have demonstrated the strength of our science and the high standards by which we operate. Avert Biolab Animal Health and Pet Nutrition, together under Biolab & Co., form a robust ecosystem to serve everyone from veterinarians in their offices to large retail chains with innovative solutions,” says Merlin Castro, Director of Avert Biolab Animal Health.
Access the article via the link: Avert and Pet Nutrition Strengthen Biolab & Co.'s Veterinary Division with Supplements, Natural Treats, and a New Factory